Location of Repository

INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER

By B. Ya. Alekseev, A. A. Krasheninnikov, K. M. Nyushko, A. S. Kalpinsky and A. D. Kaprin

Abstract

<p>Prostate cancer (PC) is one of the most burning problems of modern urologic oncology, which is attributable to the fact that the incidence of this pathology remains high. Hormone therapy (HT) is a basic treatment in patients with metastatic PC. Intermittent HT (IHT) is an effective and safe method for hormonal exposure in PC patients, as supported by the results of many trials. IHT may be recommended in the therapy of patients with PC in different clinical situations, including in patients with distant metastases. Eligard is recognized to be an effective and safe medicament to treat this category of patients. Its injection formulation once three or six months is easy-to-use for IHT.</p

Topics: рак предстательной железы, интермиттирующая гормональная терапия, элигард, лейпрорелина ацетат, Medicine, R
Publisher: ABV-press
Year: 2014
OAI identifier: oai:doaj.org/article:dd8cd0240ce8495ba8e13702beb92c63
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1996-1812 (external link)
  • https://doaj.org/toc/1726-9776 (external link)
  • http://oncourology.abvpress.ru... (external link)
  • https://doaj.org/article/dd8cd... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.